A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
This study is checking if a new medicine, GLM101, is safe and helpful for people of all ages (from 4 years old) who have a rare genetic condition called PMM2-CDG. This condition can affect how the body moves and coordinates. Researchers will compare GLM101 to a 'dummy' treatment (placebo) to see if it improves these symptoms. The study has two main parts. In the first part, some people will get GLM101 and others will get the placebo for 24 weeks. This part is 'double-blind,' meaning no one knows who is getting which treatment. After that, in the second part, everyone who wants to continue will receive GLM101 for another 24 weeks. The main goal is to see if GLM101 helps with balance and coordination.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is about a rare genetic condition called PMM2-CDG. People with this condition can have problems with their balance, movement, and coordination. Researchers are testing a new medicine, GLM101, to see if it can help improve these symptoms and if it's safe to use.
To do this, the study will involve children, teenagers, and adults who have PMM2-CDG. They will be given either GLM101 or a 'dummy' medicine (called a placebo) for 24 weeks. This helps the researchers understand if any improvements are genuinely from GLM101 or if they might have happened anyway. After this first period, everyone in the study will then have the chance to receive GLM101 for another 24 weeks.
The main thing the researchers are looking for is whether GLM101 can make a difference in how well people can move and coordinate their bodies, especially focusing on balance. They'll use a special scale to measure these changes. They will also keep a close eye on any side effects to make sure the medicine is safe.
النقاط الرئيسية
- This study is testing a new medicine (GLM101) for PMM2-CDG.
- It aims to see if GLM101 is safe and helps with movement and coordination.
- Participants will receive either GLM101 or a dummy treatment (placebo) for 24 weeks, then everyone will get GLM101 for another 24 weeks.
- People aged 4 years and older with a confirmed diagnosis of PMM2-CDG can take part.
- Regular clinic visits and assessments will be part of the study.
- يمكنك التوقف عن المشاركة في أي وقت.
من قد يكون مؤهلاً؟
To join this study, people need to be at least 4 years old. They must have been officially diagnosed with PMM2-CDG, and there needs to be a record of this diagnosis.
Also, participants need to be able to complete a specific assessment about their movement and balance. There's a certain range of scores on this assessment that helps confirm they are a good fit for the study.
If you are a woman who could become pregnant, you'll need to use reliable birth control during the study and for a short time afterwards. This is to make sure you don't become pregnant while taking the study medicine, as its effects on pregnancy are not yet known. If you are unable to become pregnant (for example, if you are very young, past menopause, or have had certain surgeries), these measures won't apply to you.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Are you 4 years old or older?
- Do you have a confirmed diagnosis of PMM2-CDG?
- Can you complete balance and movement assessments?
- If you are a woman who could become pregnant, are you willing to use effective birth control during the study?
- Are you able to attend clinic visits for infusions and assessments?
ماذا يتضمن المشاركة؟
If you join this study, you'll first have a screening period that lasts about 4 weeks. After that, the main study begins. For the first 24 weeks (Part A), you’ll receive weekly infusions of either the study medicine, GLM101, or a placebo (a dummy medicine through a drip). Neither you nor your doctor will know which one you are getting. Following this, if you wish to continue, you'll enter Part B, where everyone receives GLM101 infusions weekly for another 24 weeks. During the study, you'll have regular visits to the clinic for assessments, which will include checks on your balance and movement to see how you are doing. After your last infusion, there will be one final safety check-up visit about 4 weeks later. The total time you could be involved in the study is about a year.
المخاطر والفوائد المحتملة
المواقع (15)
- جامعة مينيسوتاالرمز البريدي المؤكدمينيابوليس، الولايات المتحدة
- كلية إيكان للطب في جبل سيناءالرمز البريدي المؤكدنيويورك، الولايات المتحدة
- مستشفى الأطفال في فيلادلفياالرمز البريدي المؤكدفيلادلفيا، الولايات المتحدة
- Seattle Children's Hospitalالرمز البريدي المؤكدسياتل، الولايات المتحدة
- UZ Leuven, Campus Gasthuisbergالرمز البريدي المؤكدلوفين، بلجيكا
- Vseobecna fakultni nemocnice v Prazeالرمز البريدي المؤكدبراغ، التشيك
- AP-HP Hopital Necker-Enfants Maladesالرمز البريدي المؤكدباريس، فرنسا
- Universitaetsklinikum Muensterالرمز البريدي المؤكدمونستر، ألمانيا
- Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marcoالرمز البريدي المؤكدكاتانيا، إيطاليا
- Azienda Ospedaliero Universitaria Pisanaالرمز البريدي المؤكدPisa, Italy
- Instytut Matki i Dzieckaالرمز البريدي المؤكدوارسو، بولندا
- Unidade Local de Saúde de Santo Antónioالرمز البريدي المؤكدPorto, Portugal
أسئلة شائعة
What is PMM2-CDG?
PMM2-CDG is a rare genetic condition that can affect how your body moves and coordinates actions, among other things.
ما هو "العلاج الوهمي"؟
A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active drug. It helps researchers see if the medicine itself is causing any changes.
كيف سأستلم الدواء الخاص بالدراسة؟
The medicine (GLM101 or placebo) will be given to you weekly through an infusion into your vein, similar to a drip.
هل سأعرف إذا كنت أحصل على الدواء الحقيقي أم الدواء الوهمي؟
During the first 24 weeks, neither you nor your doctor will know if you're receiving GLM101 or the placebo. After that, everyone will receive GLM101.
Can children join this study?
Yes, children aged 4 years and older, as well as teenagers and adults, may be able to join.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.